Report

Arteriotomy Closure Devices Market Analysis

The Arteriotomy Closure Devices Market size is estimated at USD 1.99 billion in 2025, and is expected to reach USD 2.86 billion by 2030, at a CAGR of 7.54% during the forecast period (2025-2030).

A continued shift toward same-day discharge protocols, the ubiquity of minimally invasive cardiovascular procedures, and strong evidence of reduced hemostasis times are the principal catalysts propelling the arteriotomy closure devices market. Hospitals recognize the operational gains from these solutions, with average time to ambulation dropping from 6.1 hours to 2.8 hours in electrophysiology cases that use closure devices . Large-bore structural heart interventions such as TAVR and EVAR have also accelerated demand, as their arteriotomies can exceed 20F and command premium-priced closure technologies. In parallel, emerging polymer sealants eliminate retained-implant concerns and are helping passive devices gain traction. Finally, robust reimbursement codes in North America and growing procedure volumes in Asia Pacific sustain a healthy pipeline of opportunity for established and new entrants alike.

Global Arteriotomy Closure Devices Market Trends and Insights



Increasing Prevalence of Cardiovascular & Peripheral Vascular Disorders

Global cardiovascular disease affected 655 million individuals in 2024, and peripheral arterial disease cases have risen 23% since 2010, resulting in sustained growth across diagnostic angiography, PCI, and peripheral interventions that all require reliable closure solutions. Procedure complexity in diabetic populations often demands repeat access, translating into steady, recurring demand within the arteriotomy closure devices market. Devices cut hemostasis time to around 1 minute versus 10 minutes for manual compression, allowing cath-labs to increase daily caseloads. Precision therapies targeting specific arterial beds likewise necessitate differentiated closure platforms, broadening the product mix that facilities must stock. Consequently, manufacturers that can offer comprehensive portfolios spanning sheath sizes from 5F to 24F are poised to capture incremental revenue.

Rising Geriatric Population & PCI Volumes

Patients older than 75 are the fastest-growing PCI cohort; comorbid calcification and anticoagulation elevate bleeding risk, making device-based closure preferable to manual compression. Outreach data show technical success rates of 94% and major complication rates below 1% when operators deploy closure systems in octogenarian cases. Same-day discharge adds further momentum, particularly since Medicare broadened outpatient PCI reimbursement in 2024. Health-systems also emphasize patient quality-of-life, and quicker ambulation lessens fall risk and hospital-acquired infections. Together these factors reinforce structural, long-term demand drivers for the arteriotomy closure devices market.

High ASPs of Active Closure Devices

Active closure systems range from USD 200 to 400 each, significantly above the USD 50-100 cost of manual compression kits. When large-bore TAVR cases require multiple devices, per-procedure spend can exceed USD 1,000, straining budgets in price-sensitive regions. Although bundled purchasing can offset inpatient days saved, public hospitals in emerging markets often lack capital flexibility, slowing penetration outside tier-one centers.

Other drivers and restraints analyzed in the detailed report include:

Rapid Uptake of Transradial & Same-Day Discharge Cath-Lab Programs / Growth in Large-Bore Interventions (TAVR, EVAR) Requiring Percutaneous Closure / Device-Related Complications & Steep Learning Curve /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Active platforms accounted for 59.08% of 2024 revenue within the arteriotomy closure devices market, largely on the strength of suture-mediated systems that span 5F-21F sheath sizes and deliver 97.5% technical success in real-world registries. Their immediate hemostasis supports cath-lab throughput, and broad procedural coverage underpins their market leadership.

Passive solutions, however, are set to post an 11.71% CAGR through 2030 as bio-absorbable polymers tackle previous concerns over retained collagen plugs. Early clinical experience indicates 1-minute average hemostasis and rapid resorption inside 30 days, helping passive entries secure incremental share particularly in younger and bariatric populations where foreign-body avoidance is paramount.

The Arteriotomy Closure Devices Market Report is Segmented by Product (Active Closure Devices, Passive Closure Devices), Application (Femoral Arterial Access Procedures, Radial/Brachial Arterial Access Procedures, Large-Bore Access), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America captured 43.32% of 2024 global revenue in the arteriotomy closure devices market. Medicare and private insurers reimburse closure tools without added patient cost, prompting universal adoption for PCI and electrophysiology procedures. United States operators also cite medico-legal imperatives favoring device-based closure to minimize bleeding complications. Canada's single-payer model supports closure uptake where cost-utility studies show diminished inpatient days, while Mexico's growing private hospital sector is upgrading cath-lab capabilities aligned with premium closure technologies.

Europe remains a mature but sizeable arena characterized by stringent evidence requirements and value-oriented purchasing frameworks. Germany leads implantation volumes; the United Kingdom quickly embraces cost-effective plug-based devices; and France and Italy sustain steady growth due to high procedural load and favorable coding for same-day discharge. Post-Brexit regulatory divergence complicates product registration timelines, yet EU MDR certification continues to promote technology differentiation on safety credentials.

Asia Pacific is projected to deliver the fastest regional CAGR of 8.95% to 2030 on the back of expanding cardiac care infrastructure and rising incidence of ischemic heart disease. China's investment in public and private cath-labs accelerates volume growth, while domestic device players increasingly partner with global leaders for technology transfer. Japan's advanced reimbursement and procedural sophistication underpin early adoption of bio-absorbable closure platforms. India's demand outlook remains robust, albeit tempered by acute price sensitivity that requires tiered product offerings and lean distribution.

List of Companies Covered in this Report:

Abbott Laboratories / Terumo / Medtronic / Teleflex / Cardinal Health / Haemonetics (Cardiva Medical) / Merit Medical Systems / Boston Scientific / Vivasure Medical / Otsuka Medical Devices (Veryan) / AngioDynamics / Essential Medical / InSeal Medical / Scion Cardiovascular / B. Braun / Lepu Medical / Advanced Vascular Dynamics / Endologix / Shimadzu MD Systems /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /